Maria Ganeva

Dr. Maria Ganeva


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2008 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MGMaria Ganeva
Maria Ganeva
TGTanya Gancheva
Tanya Gancheva
RLRoumiana Lazarova
Roumiana Lazarova
JTJeni Troeva
Jeni Troeva
IBIvan Baldaranov
Ivan Baldaranov
VTValentina Tzaneva
Valentina Tzaneva

1 January 2007 in Methods and Findings in Experimental and Clinical Pharmacology
Verified
Journal Article
Closed access
MGMaria Ganeva
Maria Ganeva
TGT. Gancheva
T. Gancheva
RLR. Lazarova
R. Lazarova
YTY. Tzvetanova
Y. Tzvetanova
EHE. Hristakieva
E. Hristakieva
The objective of this study was to evaluate the clinical pattern and risk factors for adverse drug reactions (ADRs) in patients hospitalized in a specialized dermatology department. A prospective study was conducted in the Clinic of Dermatology and Venereology in Stara Zagora for a 5-year period. ADRs were classified by type, severity and causality. Case-causality was scored according to Naranjo et al. (1981). A total of 1041 admissions were analyzed. ADRs occurred in 147 patients. Cutaneous reactions represented the most common ADRs followed by endocrine/metabolic, cardiovascular and gastrointestinal disorders. The prevalent clinical patterns of cutaneous ADRs were exanthematous and urticarial. ADRs were almost evenly distributed as type A and type B reactions. Drug classes most frequently responsible for ADRs were glucocorticosteroids (GLCs) and antiinfective agents. The factors significantly associated with ADRs were the use of GLCs (OR 11.11; 95% CI 6.69-18.43), antiinfective agents (OR 1.48; 95% CI 1.04-2.11) and older age. Patients hospitalized in a dermatology department may develop ADRs with multiorgan clinical presentation. The most important risk factors for ADRs in this sample of patients were the use of GLCs, antiinfective agents and older age. The study establishes a specific ADR risk profile of patients with dermatological disorders in a hospital setting.

1 February 2024 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MGMaria Ganeva
Maria Ganeva
TGTanya Gancheva
Tanya Gancheva
KMKaren Manuelyan
Karen Manuelyan
EHEvgenya Hristakieva
Evgenya Hristakieva
Objectives: Bullous pemphigoid (BP) is a rare, autoimmune, blistering disease in elderly patients that can be triggered by external factors including drugs. Drug-induced bullous pemphigoid (DIBP) does not always follow a self-limiting course after the withdrawal of the offending drug. Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins seem to be associated with a significant risk of inducing BP. Case presentation: We report 2 cases of BP attributed to the DPP-4 inhibitor linagliptin. In both cases, the clinical manifestation was strongly suggestive of BP. The diagnosis was verified by histology and direct immunofluorescence (DIF). Linagliptin and all other possible drug triggers of BP were discontinued after consultation with an endocrinologist and a cardiologist. Systemic treatment of BP consisted of methylprednisolone and tetracycline. During the follow-up period, one of the patients suffered a fatal brain stroke while the other was managed with reduced doses of corticosteroids. Conclusion: The proper management of autoimmune bullous skin disorders in elderly patients includes a scrupulous assessment of plausible drug triggers. Systemic corticosteroids for treating severe cases of DIBP can worsen concomitant diseases which often necessitates multidisciplinary care.

1 January 2008
Verified
Journal Article
Closed access
MGMaria Ganeva
Maria Ganeva
DGDamianka P Getova
Damianka P Getova
VGVesselina G Gadjeva
Vesselina G Gadjeva

30 August 2013
Verified
Journal Article
Closed access
MGMaria Ganeva
Maria Ganeva
TGTanya Gancheva
Tanya Gancheva
JTJeni Troeva
Jeni Troeva
NKNataliya Kiriyak
Nataliya Kiriyak
EHEvgenia Hristakieva
Evgenia Hristakieva

1 November 2014 in Journal of Biomedical and Clinical Research
Verified
Journal Article
Open access
PDF file
MGMaria Ganeva
Maria Ganeva
TGTanya T. Gancheva
Tanya T. Gancheva
IBIvan D. Baldaranov
Ivan D. Baldaranov
NKNataliya J. Kiriyak
Nataliya J. Kiriyak
EHEvgeniya H. Hristakieva
Evgeniya H. Hristakieva
Methotrexate (MTX) is a cytostatic agent used in oncology. Because of its immunosuppressive properties, MTX is also used in autoimmune disorders. Low-dose MTX regimens in the treatment of rheumatoid arthritis and severe psoriasis are considered to be safe. However, pharmacovigilance centers warn of serious and even fatal incidents due to errors in oral MTX administration. The aim of this case series presentation was to identify the specific factors related to the development of adverse drug reactions (ADRs) induced by MTX. A prospective pharmacovigilance study was conducted at the Clinic of Dermatology, University Hospital, Stara Zagora. We report 3 cases of patients with psoriasis vulgaris in which severe haematological abnormalities associated with previous administration of MTX were detected during hospitalization. A 73-year old female with malaise, vomiting and oral ulcers who had taken approximately 120 mg MTX was found to have pancytopenia. A 59-year old male hospitalized for psoriatic erythroderma who had erroneously taken 10 mg MTX daily instead of weekly for 8 days, was diagnosed with bicytopenia and toxic hepatitis. An 88-year old male with psoriatic arthritis presented with aphthous stomatitis, erosive crusted lesions, ecchymoses and aplastic anemia 2 weeks after treatment with 12.5 mg MTX once weekly plus i.m. Movalis®, followed by Diclophenac Duo®. The main predisposing factors for the development of these ADRs were patient-related dosage errors and concomitant administration of NSAIDs. Safe use of oral MTX requires clear dosing instructions and strict patient compliance. Potential drug interactions of MTX with other drugs should also be considered.